Эндокринная артериальная гипертензия: причины развития, принципы диагностики и лечения. Лекция для врачей
Титова В.В., Кисляк О.А., Демидова Т.Ю. Эндокринная артериальная гипертензия: причины развития, принципы диагностики и лечения. Лекция для врачей. FOCUS Эндокринология. 2021; 4: 31–38. DOI: 10.47407/ef2021.2.4.0047
Titova V.V., Kislyak O.A., Demidova T.Yu. Endocrine arterial hypertension: causes of development, principles of diagnosis and treatment. Lecture for doctors. FOCUS Endocrinology. 2021; 4: 31–38. DOI: 10.47407/ef2021.2.4.0047
Вторичная артериальная гипертензия эндокринного генеза (ЭАГ) – форма повышения артериального давления (АД), в основе которой ле жит заболевание эндокринного органа, ответственного хотя бы косвенно за регуляцию АД. В этих случаях артериальная гипертензия (АГ) представляется лишь одним из симптомов основного заболевания. Эндокринные заболевания, ассоциированные с вторичной гипертензией, могут иметь уникальные клинические особенности, а также быть бессимптомными и выявляться во время лечения резистентной АГ (рефрактерной к стандартной антигипертензивной терапии). Наиболее часто причинами ЭАГ являются заболевания надпочечников и гипофиза. В данном обзоре рассмотрены этиопатогенетические звенья, принципы диагностики и лечения заболеваний, лежащих в основе развития ЭАГ.
Ключевые слова: эндокринная артериальная гипертензия, первичный гиперальдостеронизм, врожденная дисфункция коры надпочечников, феохромоцитома, параганглиома, синдром Кушинга, гипотиреоз, тиреотоксикоз, гиперпаратиреоз.
Ключевые слова: эндокринная артериальная гипертензия, первичный гиперальдостеронизм, врожденная дисфункция коры надпочечников, феохромоцитома, параганглиома, синдром Кушинга, гипотиреоз, тиреотоксикоз, гиперпаратиреоз.
1. Young WF. Endocrine hypertension. Ed. by Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. Williams textbook of endocrinology, 13th edn. New York: Elsevier, 2015.
2. Pappachan JM, Buch HN. Endocrine Hypertension: A Practical Approach. Oncology Letters. 2016; 28: 215–37. DOI: 10.1007/5584_2016_26215–37
3. Mulatero P, Stowasser M, Loh K-C et al. Increased Diagnosis of Primary Al-dosteronism, Including Surgically Correctable Forms, in Centers from Five Continents. J Clin Endocrinol Metab 2004; 89 (3): 1045–50. DOI: 10.1210/jc.2003-031337
4. Rossi GP, Bernini G, Caliumi C et al. A Prospective Study of the Prevalence of Primary Aldosteronism in 1,125 Hypertensive Patients. J Am Coll Cardiol 2006; 48 (11): 2293–2300. DOI: 10.1016/j.jacc.2006.07.059
5. Young WF. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med 2019; 285 (2): 126–48. DOI: 10.1111/joim.12831
6. Funder JW, Carey RM, Mantero F et al. The management of primary aldos-teronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101 (5): 1889–
916. DOI: 10.1210/jc.2015-4061
7. Strajina V, al-Hilli Z, Andrews JC et al. Primary aldosteronism: making sense of partial data sets from failed adrenal venous sampling-suppression of adrenal aldosterone production can be used in clinical decision making. Surgery 2018; 163 (4): 801–6. DOI: 10.1016/j.surg.2017.10.012
8. Fischer E, Beuschlein F, Bidlingmaier M, Reincke M. Commentary on the En-docrine Society Practice Guidelines: Consequences of adjustment of antihy-pertensive medication in screening of primary aldosteronism. Rev Endocr Metab Disord 2011; 12 (1): 43–8. DOI: 10.1007/s11154-011-9163-7
9. Hinz L, Pacaud D, Kline G. Congenital adrenal hyperplasia causing hyper-tension: an illustrative review. J Hum Hypertens 2018; 32 (2): 150–7. DOI: 10.1038/s41371-017-0002-5
10. Bulsari K, Falhammar H. Clinical perspectives in congenital adrenal hyper-plasia due to 11β-hydroxylase deficiency. Endocrine 2017; 55 (1): 19–36. DOI: 10.1007/s12020-016-1189-x
11. Auchus RJ. Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic. J Steroid Biochem Mol Biol 2017; 165 (Pt A): 71–8. DOI: 10.1016/j.jsbmb.2016.02.002
12. Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and Paragan-glioma. N Engl J Med 2019; 381 (6): 552–65. DOI: 10.1056/NEJMra1806651
13. Gruber LM, Hartman RP, Thompson GB et al. Pheochromocytoma charac-teristics and behavior differ depending on method of discovery. J Clin En-docrinol Metab 2019; 104 (5): 1386–93. DOI: 10.1210/jc.2018-01707
14. Lenders JW, Duh QY, Eisenhofer G et al. Pheochromocytoma and paragan-glioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99: 1915–42. DOI: 10.1210/jc.2014-1498
15. Pappachan JM, Raskauskiene D, Sriraman R et al. Diagnosis and manage-ment of pheochromocytoma: a practical guide to clinicians. Curr Hypertens Rep 2014; 16: 442. DOI: 10.1007/s11906-014-0442-z
16. Nieman LK, Biller BM, Findling JW et al. The diagnosis of Cushing’s syn-drome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 1526–40. DOI: 10.1210/jc.2008-0125
17. Donadille B, Groussin L, Waintrop C et al. Management of Cushing’s syn-drome due to ectopic adrenocorticotropin secretion with 1, ortho-1, para’-dichlorodiphenyl-dichloro-ethane: findings in 23 patients from a single cen-ter. J Clin Endocrinol Metab 2010: 95: 537–44.
18. Fleseriu M, Biller BM, Findling JW et al. Mifepristone, a glucocorticoid re-ceptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012; 97 (6): 2039–49. DOI: 10.1210/jc.2011-3350
19. Pivonello R, De Leo M, Cozzolino A et al. A. The Treatment of Cushing's Dis-ease. Endocr Rev 2015; 36 (4): 385–486. DOI: 10.1210/er.2013-1048
20. Capatina C, Wass JA. 60 years of neuroendocrinology: acromegaly. J En-docrinol 2015; 226: T141–60. DOI: 10.1530/JOE-15-0109
21. Katznelson L. Approach to the patient with persistent acromegaly after pi-tuitary surgery. J Clin Endocrinol Metab 2010; 95: 4114–23. DOI: 10.1210/jc.2010-0670
22. Katznelson L, Laws ER, Melmed S et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99: 3933–51. DOI: 10.1210/jc.2014-2700
23. Corica G, Ceraudo M, Campana Cet al. Octreotide-Resistant Acromegaly: Challenges and Solutions. Ther Clin Risk Manag 2020; 16: 379–91. DOI: 10.2147/TCRM.S183360
24. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501–9.
25. Jawaid I, Rajesh S. Hyperparathyroidism (primary) NICE guideline: diagno-sis, assessment, and initial management. Br J Gen Pract 2020; 70 (696): 362–3. DOI: 10.3399/bjgp20X710717
2. Pappachan JM, Buch HN. Endocrine Hypertension: A Practical Approach. Oncology Letters. 2016; 28: 215–37. DOI: 10.1007/5584_2016_26215–37
3. Mulatero P, Stowasser M, Loh K-C et al. Increased Diagnosis of Primary Al-dosteronism, Including Surgically Correctable Forms, in Centers from Five Continents. J Clin Endocrinol Metab 2004; 89 (3): 1045–50. DOI: 10.1210/jc.2003-031337
4. Rossi GP, Bernini G, Caliumi C et al. A Prospective Study of the Prevalence of Primary Aldosteronism in 1,125 Hypertensive Patients. J Am Coll Cardiol 2006; 48 (11): 2293–2300. DOI: 10.1016/j.jacc.2006.07.059
5. Young WF. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med 2019; 285 (2): 126–48. DOI: 10.1111/joim.12831
6. Funder JW, Carey RM, Mantero F et al. The management of primary aldos-teronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101 (5): 1889–
916. DOI: 10.1210/jc.2015-4061
7. Strajina V, al-Hilli Z, Andrews JC et al. Primary aldosteronism: making sense of partial data sets from failed adrenal venous sampling-suppression of adrenal aldosterone production can be used in clinical decision making. Surgery 2018; 163 (4): 801–6. DOI: 10.1016/j.surg.2017.10.012
8. Fischer E, Beuschlein F, Bidlingmaier M, Reincke M. Commentary on the En-docrine Society Practice Guidelines: Consequences of adjustment of antihy-pertensive medication in screening of primary aldosteronism. Rev Endocr Metab Disord 2011; 12 (1): 43–8. DOI: 10.1007/s11154-011-9163-7
9. Hinz L, Pacaud D, Kline G. Congenital adrenal hyperplasia causing hyper-tension: an illustrative review. J Hum Hypertens 2018; 32 (2): 150–7. DOI: 10.1038/s41371-017-0002-5
10. Bulsari K, Falhammar H. Clinical perspectives in congenital adrenal hyper-plasia due to 11β-hydroxylase deficiency. Endocrine 2017; 55 (1): 19–36. DOI: 10.1007/s12020-016-1189-x
11. Auchus RJ. Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic. J Steroid Biochem Mol Biol 2017; 165 (Pt A): 71–8. DOI: 10.1016/j.jsbmb.2016.02.002
12. Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and Paragan-glioma. N Engl J Med 2019; 381 (6): 552–65. DOI: 10.1056/NEJMra1806651
13. Gruber LM, Hartman RP, Thompson GB et al. Pheochromocytoma charac-teristics and behavior differ depending on method of discovery. J Clin En-docrinol Metab 2019; 104 (5): 1386–93. DOI: 10.1210/jc.2018-01707
14. Lenders JW, Duh QY, Eisenhofer G et al. Pheochromocytoma and paragan-glioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99: 1915–42. DOI: 10.1210/jc.2014-1498
15. Pappachan JM, Raskauskiene D, Sriraman R et al. Diagnosis and manage-ment of pheochromocytoma: a practical guide to clinicians. Curr Hypertens Rep 2014; 16: 442. DOI: 10.1007/s11906-014-0442-z
16. Nieman LK, Biller BM, Findling JW et al. The diagnosis of Cushing’s syn-drome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 1526–40. DOI: 10.1210/jc.2008-0125
17. Donadille B, Groussin L, Waintrop C et al. Management of Cushing’s syn-drome due to ectopic adrenocorticotropin secretion with 1, ortho-1, para’-dichlorodiphenyl-dichloro-ethane: findings in 23 patients from a single cen-ter. J Clin Endocrinol Metab 2010: 95: 537–44.
18. Fleseriu M, Biller BM, Findling JW et al. Mifepristone, a glucocorticoid re-ceptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012; 97 (6): 2039–49. DOI: 10.1210/jc.2011-3350
19. Pivonello R, De Leo M, Cozzolino A et al. A. The Treatment of Cushing's Dis-ease. Endocr Rev 2015; 36 (4): 385–486. DOI: 10.1210/er.2013-1048
20. Capatina C, Wass JA. 60 years of neuroendocrinology: acromegaly. J En-docrinol 2015; 226: T141–60. DOI: 10.1530/JOE-15-0109
21. Katznelson L. Approach to the patient with persistent acromegaly after pi-tuitary surgery. J Clin Endocrinol Metab 2010; 95: 4114–23. DOI: 10.1210/jc.2010-0670
22. Katznelson L, Laws ER, Melmed S et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99: 3933–51. DOI: 10.1210/jc.2014-2700
23. Corica G, Ceraudo M, Campana Cet al. Octreotide-Resistant Acromegaly: Challenges and Solutions. Ther Clin Risk Manag 2020; 16: 379–91. DOI: 10.2147/TCRM.S183360
24. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501–9.
25. Jawaid I, Rajesh S. Hyperparathyroidism (primary) NICE guideline: diagno-sis, assessment, and initial management. Br J Gen Pract 2020; 70 (696): 362–3. DOI: 10.3399/bjgp20X710717